Healthcare, Pharma & Life Sciences

PLAINSBORO, N.J. – November 07, 2026 -- Novo Nordisk reported that adults with metabolic dysfunction-associated steatohepatitis (MASH) who started semaglutide 2.4 mg once weekly lost a statistically significant mean 18.9 lb (8.6 kg; about 8%) from baseline versus patients on resmetirom at six months, according to real-world data presented at AASLD The Liver Meeting 2026 in Denver.

PLATINUM-Truveta compares 2,873 semaglutide patients with 2,285 on resmetirom

The retrospective cohort study drew on de-identified electronic medical records from 30 US health systems in the Truveta database, covering June 2021 through March 2026. Semaglutide 2.4 mg was also associated with significantly greater reductions than resmetirom in AST and some cardiometabolic measures. Researchers assessed ALT, AST, body weight, HbA1c, platelets, triglycerides, HDL and LDL at three and six months.

REHOVOT, Israel – November 05, 2026 -- Evogene Ltd. (Nasdaq: EVGN; TASE: EVGN) will release its third-quarter 2026 financial results on Thursday, November 19, 2026, the computational chemistry company announced.

Management will host a conference call the same day at 9:00 AM Eastern Time (4:00 PM Israel time) to discuss the results. Attendance via Zoom requires advance registration.

Evogene will publish a full conference recording on its website a few days after the call

The company plans to make the entire conference available online shortly after the event, giving investors who miss the live session access to management's commentary.

BOSTON – November 06, 2026 -- Skyhawk Therapeutics has dosed the first U.S. patients in its global pivotal FALCON-HD study of SKY-0515 in Huntington's disease (HD). More than 50,000 doses have been administered to date across more than 30 study sites in 10 countries.

CenExel Colorado site opens U.S. dosing, with Beth Israel Deaconess next

Dosing in the U.S. began at the CenExel Movement Disorder Center in Colorado. Additional U.S. sites, including Beth Israel Deaconess Medical Center, are expected to begin dosing in the coming weeks. Samuel Frank, MD, Director of the HDSA Center of Excellence at Beth Israel Deaconess and a FALCON-HD investigator, expects dosing there before the end of 2026. He described Phase 1/2 results to date as very encouraging.

Berlin – November 06, 2026 -- Germany's Innovation Fund has paid out more than €2 billion since 2016, yet only 24% of its completed new-care-model projects received a decision to examine continuation in routine care, according to AOK-Bundesverband. The statutory health insurer presented its proposals at a congress marking the fund's tenth anniversary, hosted by the Innovation Committee at the Federal Joint Committee (G-BA).

Half of 146 completed care-model projects received no recommendation

The fund has supported more than 850 projects. Of these, 270 fall under new care models and 591 under health services research. Half of the 146 completed new-care-model projects received no recommendation for further use.

New York – November 06, 2026 -- Kos Biotechnology Partners has invested in Fathom Therapeutics' oversubscribed $55 million Series A, which was led by Sutter Hill Ventures, to back a drug discovery platform that combines quantum chemistry, physics-based simulation and artificial intelligence.

Kos commits capital through its inaugural life sciences fund

The investment came through Kos BioVentures, the firm's first life sciences fund. Kos, based in New York and Athens, manages $125 million in assets. It invests across all development stages in therapeutic breakthroughs, biodefense and tech-enabled pharma services.

Cambridge, Mass. – November 06, 2026 -- CREATE Medicines, Inc. says it has treated more than 80 patients with in vivo CAR therapy, which it describes as the largest clinical dataset in the field. The company is now taking its four clinical-stage programs to investors and prospective partners at the Jefferies Global Healthcare Conference in London.

CREATE schedules one-on-one meetings at Jefferies London on Nov. 16-19, 2026

Management will hold one-on-one meetings at the Waldorf Hilton and ME London during the conference, which runs from Nov. 16 to 19, 2026. CEO and Co-Founder Daniel Getts, PhD, and Chief Medical Officer Matthew Maurer, MD, will represent the clinical-stage biotech.

Investors must request meetings through their Jefferies representative. Prospective partners can contact the company's business development team directly.

Guangzhou – November 06, 2026 -- China's National Medical Products Administration (NMPA) has approved Bio-Thera Solutions' BAT2506, the first golimumab biosimilar cleared in the country, the Shanghai-listed company (688177.SH) said.

ASHULI is cleared for rheumatoid arthritis and ankylosing spondylitis

BAT2506 will be sold in China under the brand name ASHULI. The NMPA approved it for two indications: rheumatoid arthritis and ankylosing spondylitis.

Golimumab is a human IgG1 monoclonal antibody that targets tumor necrosis factor alpha (TNF-α). Binding to TNF-α reduces the inflammatory markers CRP, IL-6, ICAM-1, MMP-3 and VEGF.

Bio-Thera adds its sixth approved biosimilar in China

CEO Shengfeng Li said ASHULI is the company's sixth biosimilar approved in China. He said biosimilars "have an important role in expanding patient access to important biologics."

SAN FRANCISCO – November 06, 2026 -- Avive Solutions, Inc. will deploy 25 Avive Connect AEDs as First Aid Sponsor of the 2026 Good Life Halfsy, Nebraska's largest half marathon, where 9,500 registered runners and more than 20,000 spectators are expected.

The 13th annual event in Lincoln, Nebraska, is projected to generate a $3.4 million economic impact for the region. Producer Pink Gorilla Events has generated more than $1.1 million in donations to local charities and nonprofits through its races.

Medical volunteers will carry Avive AEDs along the 13.1-mile course

The event's medical volunteers will carry the devices, putting them in the hands of trained responders along the route. A Good Life Halfsy co-race director said the added units are meant to strengthen race-day emergency preparedness for runners, spectators and volunteers.

Laval – November 06, 2026 -- Only 62.0% of patients hospitalized with severe alcohol-associated hepatitis (AH) in the United States were estimated to survive 12 months, according to a real-world study from Bausch Health Companies Inc. and its gastroenterology unit, Salix Pharmaceuticals.

Study of 1,630 US adults tracks rehospitalization and transplant rates

The companies are presenting the poster, "Clinical Burden and Outcomes in a Large Real-World Cohort of Patients Hospitalized with Severe Alcohol-Associated Hepatitis," at the American Association for the Study of Liver Diseases' The Liver Meeting 2026. The meeting runs November 5-9 in Denver, Colorado. The cohort comprised 1,630 adults.

Rehospitalization climbs from 31.4% at 30 days to 69.1% at 12 months

Within 30 days of discharge, 31.4% of patients were rehospitalized. The estimated rate reached 69.1% by 12 months. The estimated liver transplantation rate at 12 months was 8.5%.

Boston – November 06, 2026 -- Servier will present nine abstracts, including five oral presentations, at the 31st Society for Neuro-Oncology (SNO) Annual Meeting, held November 12-15 in Philadelphia. The package covers both of its glioma therapies: VORANIGO (vorasidenib) in IDH-mutant glioma and OJEMDA (tovorafenib) in BRAF-altered pediatric low-grade glioma (pLGG).

Four-year FIREFLY-1 data to cover retreatment after progression in pLGG

One oral presentation will deliver updated results from the four-year follow-up of the Phase 2 FIREFLY-1 study of OJEMDA in relapsed or refractory BRAF-altered pLGG. The analysis includes data on post-treatment observation and on retreatment with OJEMDA after disease progression.